• Biovica reported new DiviTum TKa data published in Clinical Cancer Research, with results already presented in the peer-reviewed article.
• In a small Phase I trial in advanced HR+/HER2- metastatic breast cancer, low early TKa levels aligned with clinical benefit.
• Higher early TKa levels were seen in patients who did not benefit, supporting the test’s role in early treatment assessment.
• The findings were exploratory in 16 patients, with validation planned in an ongoing Phase II study that includes other biomarkers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.